Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet.

Pellizzon ACA.

Int Braz J Urol. 2019 Jan-Feb;45(1):5-9. doi: 10.1590/S1677-5538.IBJU.2018.0734. No abstract available.

2.

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F.

Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20.

PMID:
27339116
3.

Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Falivene S, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Piscitelli R, Berretta M, Muto P, Facchini G.

Oncotarget. 2017 Mar 7;8(10):17383-17395. doi: 10.18632/oncotarget.14798. Review.

4.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O'Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E.

Lancet Oncol. 2015 Dec;16(16):1605-16. doi: 10.1016/S1470-2045(15)00280-6. Epub 2015 Oct 28.

5.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators.

Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Erratum in: Lancet Oncol. 2016 Aug;17 (8):e321.

6.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, Hall E.

Lancet Oncol. 2012 Jan;13(1):43-54. doi: 10.1016/S1470-2045(11)70293-5. Epub 2011 Dec 12.

7.

Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.

Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF.

Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):943-55.

PMID:
12605972
8.

Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis.

Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, Dos Reis RB.

Core Evid. 2013;8:1-13. doi: 10.2147/CE.S41178. Epub 2013 Mar 7.

9.

Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.

Di Franco R, Borzillo V, Ravo V, Ametrano G, Cammarota F, Rossetti S, Romano FJ, D'Aniello C, Cavaliere C, Iovane G, Porricelli MA, Muto M, Berretta M, Facchini G, Muto P.

Eur Rev Med Pharmacol Sci. 2017 Aug;21(16):3563-3575. Review.

10.

Moderately Hypofractionated Radiotherapy in Node-positive Prostate Cancer.

Mallick I, Das A, Arunsingh M.

Clin Oncol (R Coll Radiol). 2019 Apr;31(4):260-264. doi: 10.1016/j.clon.2019.01.004. Epub 2019 Feb 2.

PMID:
30718087
11.

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.

Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX.

Lancet Oncol. 2019 Mar;20(3):352-360. doi: 10.1016/S1470-2045(18)30813-1. Epub 2019 Jan 30.

PMID:
30711522
12.

The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.

Hashimoto Y, Motegi A, Akimoto T, Mitsuhashi N, Iizuka J, Tanabe K, Ishii Y, Kono S, Izumi S, Karasawa K.

Int J Clin Oncol. 2018 Feb;23(1):165-172. doi: 10.1007/s10147-017-1175-1. Epub 2017 Jul 31.

PMID:
28758177
13.

Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience.

Barbosa Neto O, Souhami L, Faria S.

Cancer Radiother. 2015 Oct;19(6-7):431-6. doi: 10.1016/j.canrad.2015.05.015. Epub 2015 Aug 14.

PMID:
26278988
14.

"Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.

Marvaso G, Riva G, Ciardo D, Gandini S, Fodor C, Zerini D, Colangione SP, Timon G, Comi S, Cambria R, Cattani F, De Cobelli O, Orecchia R, Jereczek-Fossa BA.

Med Oncol. 2018 May 10;35(6):96. doi: 10.1007/s12032-018-1155-y.

PMID:
29748830
15.
16.

Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.

Tramacere F, Arcangeli S, Pignatelli A, Castagna R, Portaluri M.

Anticancer Res. 2015 May;35(5):3049-54.

PMID:
25964594
17.

Acute radiation dermatitis and pneumonitis in Japanese breast cancer patients with whole breast hypofractionated radiotherapy compared to conventional radiotherapy.

Osako T, Oguchi M, Kumada M, Nemoto K, Iwase T, Yamashita T.

Jpn J Clin Oncol. 2008 May;38(5):334-8. doi: 10.1093/jjco/hyn030. Epub 2008 Apr 16.

PMID:
18417501
18.

Stereotactic Body Radiotherapy for Primary Prostate Cancer.

Kothari G, Loblaw A, Tree AC, van As NJ, Moghanaki D, Lo SS, Ost P, Siva S.

Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633. doi: 10.1177/1533033818789633.

19.

Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.

Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1271-8. doi: 10.1016/j.ijrobp.2010.07.1984. Epub 2010 Oct 8.

PMID:
20934277
20.

Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.

Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escudé L.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):50-7. doi: 10.1016/j.ijrobp.2009.07.1689. Epub 2009 Nov 10.

PMID:
19910135

Supplemental Content

Support Center